+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Glucose Monitoring Devices Market By Device, By Patient Type: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • PDF Icon

    Report

  • 216 Pages
  • July 2024
  • Region: Global
  • Allied Market Research
  • ID: 5993947
The glucose monitoring devices market was valued at $14.7 billion in 2023 and is projected to reach $38.9 billion by 2033, growing at a CAGR of 10.2% from 2024 to 2033.

Glucose monitoring involves the measuring and tracking the glucose levels in the blood or interstitial fluid of individuals. It is an essential routine for individuals with diabetes for effective management, as it provides data about fluctuations in blood sugar levels throughout the day in response to several factors such as food intake, stress, physical activity, and medication. The real-time or periodic glucose readings provided glucose monitoring devices allow individuals to make informed decisions regarding dietary choices, medication dosage, and lifestyle adjustments. Glucose monitoring devices are critical equipment for the prevention of short-term and long-term complications associated with diabetes.

Increase in prevalence of lifestyle diseases, including obesity and diabetes, is a major driver of the glucose monitoring devices market. In addition, the demand for self-monitoring portable devices is surging among individuals, hence augmenting the development of the market. Non-invasive glucose monitoring devices are trending in the market currently. Optical sensors and microneedle patches are among the most common equipment available in the market. Furthermore, the integration of data analytics is acquiring traction from individuals and healthcare providers as it aids to identify patterns and trends, thereby assisting in proactive management and prevention of diseases.

However, a large base of individuals adheres to the traditional method of glucose testing owing to high confidence in its results, which presents challenges for the widespread adoption of new & innovative glucose monitoring devices. Moreover, the approval process of new monitoring devices is highly stringent and lengthy, which often delays the introduction of novel products into the market. Contrarily, the constant efforts of scientists to launch innovative products present lucrative opportunities for the expansion of the market. For instance, researchers of the King Abdullah University of Science & Technology, Saudi Arabia developed a prototype for a sensor that measures glucose levels using saliva. This device is projected to be a simple, quick, and painless way for individuals to measure blood glucose in the future.

Segment Review

The glucose monitoring devices market is segmented into device, patient type, end user, and region. On the basis of device, the market is divided into blood glucose meters, continuous glucose monitoring systems, flash glucose monitoring systems, smartphone apps, and wearables. By patient type, it is bifurcated into type 1 diabetes and type 2 diabetes. According to end user, it is classified into hospitals & clinics, home care settings, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of device, the continuous glucose monitoring devices segment generated the highest revenue in the market in 2023.

By patient type, the type 1 diabetes segment was the highest shareholder in 2023.

According to end user, the home care settings segment was the highest revenue generator in 2023.

Competition Analysis

The major players operating in the global glucose monitoring devices market include Menarini Diagnostics S.R.L., Senseonics, A., Novo Nordisk A/S, GlySens Incorporated, Johnson & Johnson, DexCom, Inc., Medtronic plc, F. Hoffman-La Roche Ltd, Abbott laboratories, and B. Braun SE. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Device

  • Blood Glucose Meters
  • Continuous Glucose Monitoring Systems
  • Flash Glucose Monitoring Systems
  • Smartphone Apps and Wearables

By Patient Type

  • Type 1 Diabetes
  • Type 2 Diabetes

By End User

  • Hospitals and Clinics
  • Home Care Settings
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

Key Market Players

  • Menarini Diagnostics S.R.L.
  • Senseonics, A.
  • Novo Nordisk A/S
  • GlySens Incorporated
  • Johnson & Johnson
  • DexCom, Inc.
  • Medtronic plc
  • F. Hoffman-La Roche Ltd
  • Abbott laboratories
  • B. Braun SE

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4: GLUCOSE MONITORING DEVICES MARKET, BY DEVICE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Device
4.2. Blood Glucose Meters
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Continuous Glucose Monitoring Systems
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Flash Glucose Monitoring Systems
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
4.5. Smartphone Apps And Wearables
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, By Region
4.5.3. Market Share Analysis, By Country
CHAPTER 5: GLUCOSE MONITORING DEVICES MARKET, BY PATIENT TYPE
5.1. Market Overview
5.1.1 Market Size and Forecast, By Patient Type
5.2. Type 1 Diabetes
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Type 2 Diabetes
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: GLUCOSE MONITORING DEVICES MARKET, BY END USER
6.1. Market Overview
6.1.1 Market Size and Forecast, By End User
6.2. Hospitals And Clinics
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Home Care Settings
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Others
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: GLUCOSE MONITORING DEVICES MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Device
7.2.3. Market Size and Forecast, By Patient Type
7.2.4. Market Size and Forecast, By End User
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Glucose Monitoring Devices Market
7.2.6.1. Market Size and Forecast, By Device
7.2.6.2. Market Size and Forecast, By Patient Type
7.2.6.3. Market Size and Forecast, By End User
7.2.7. Canada Glucose Monitoring Devices Market
7.2.7.1. Market Size and Forecast, By Device
7.2.7.2. Market Size and Forecast, By Patient Type
7.2.7.3. Market Size and Forecast, By End User
7.2.8. Mexico Glucose Monitoring Devices Market
7.2.8.1. Market Size and Forecast, By Device
7.2.8.2. Market Size and Forecast, By Patient Type
7.2.8.3. Market Size and Forecast, By End User
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Device
7.3.3. Market Size and Forecast, By Patient Type
7.3.4. Market Size and Forecast, By End User
7.3.5. Market Size and Forecast, By Country
7.3.6. France Glucose Monitoring Devices Market
7.3.6.1. Market Size and Forecast, By Device
7.3.6.2. Market Size and Forecast, By Patient Type
7.3.6.3. Market Size and Forecast, By End User
7.3.7. Germany Glucose Monitoring Devices Market
7.3.7.1. Market Size and Forecast, By Device
7.3.7.2. Market Size and Forecast, By Patient Type
7.3.7.3. Market Size and Forecast, By End User
7.3.8. Italy Glucose Monitoring Devices Market
7.3.8.1. Market Size and Forecast, By Device
7.3.8.2. Market Size and Forecast, By Patient Type
7.3.8.3. Market Size and Forecast, By End User
7.3.9. Spain Glucose Monitoring Devices Market
7.3.9.1. Market Size and Forecast, By Device
7.3.9.2. Market Size and Forecast, By Patient Type
7.3.9.3. Market Size and Forecast, By End User
7.3.10. UK Glucose Monitoring Devices Market
7.3.10.1. Market Size and Forecast, By Device
7.3.10.2. Market Size and Forecast, By Patient Type
7.3.10.3. Market Size and Forecast, By End User
7.3.11. Rest Of Europe Glucose Monitoring Devices Market
7.3.11.1. Market Size and Forecast, By Device
7.3.11.2. Market Size and Forecast, By Patient Type
7.3.11.3. Market Size and Forecast, By End User
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Device
7.4.3. Market Size and Forecast, By Patient Type
7.4.4. Market Size and Forecast, By End User
7.4.5. Market Size and Forecast, By Country
7.4.6. China Glucose Monitoring Devices Market
7.4.6.1. Market Size and Forecast, By Device
7.4.6.2. Market Size and Forecast, By Patient Type
7.4.6.3. Market Size and Forecast, By End User
7.4.7. Japan Glucose Monitoring Devices Market
7.4.7.1. Market Size and Forecast, By Device
7.4.7.2. Market Size and Forecast, By Patient Type
7.4.7.3. Market Size and Forecast, By End User
7.4.8. India Glucose Monitoring Devices Market
7.4.8.1. Market Size and Forecast, By Device
7.4.8.2. Market Size and Forecast, By Patient Type
7.4.8.3. Market Size and Forecast, By End User
7.4.9. South Korea Glucose Monitoring Devices Market
7.4.9.1. Market Size and Forecast, By Device
7.4.9.2. Market Size and Forecast, By Patient Type
7.4.9.3. Market Size and Forecast, By End User
7.4.10. Australia Glucose Monitoring Devices Market
7.4.10.1. Market Size and Forecast, By Device
7.4.10.2. Market Size and Forecast, By Patient Type
7.4.10.3. Market Size and Forecast, By End User
7.4.11. Rest of Asia-Pacific Glucose Monitoring Devices Market
7.4.11.1. Market Size and Forecast, By Device
7.4.11.2. Market Size and Forecast, By Patient Type
7.4.11.3. Market Size and Forecast, By End User
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Device
7.5.3. Market Size and Forecast, By Patient Type
7.5.4. Market Size and Forecast, By End User
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Glucose Monitoring Devices Market
7.5.6.1. Market Size and Forecast, By Device
7.5.6.2. Market Size and Forecast, By Patient Type
7.5.6.3. Market Size and Forecast, By End User
7.5.7. South Africa Glucose Monitoring Devices Market
7.5.7.1. Market Size and Forecast, By Device
7.5.7.2. Market Size and Forecast, By Patient Type
7.5.7.3. Market Size and Forecast, By End User
7.5.8. Saudi Arabia Glucose Monitoring Devices Market
7.5.8.1. Market Size and Forecast, By Device
7.5.8.2. Market Size and Forecast, By Patient Type
7.5.8.3. Market Size and Forecast, By End User
7.5.9. Rest of LAMEA Glucose Monitoring Devices Market
7.5.9.1. Market Size and Forecast, By Device
7.5.9.2. Market Size and Forecast, By Patient Type
7.5.9.3. Market Size and Forecast, By End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Menarini Diagnostics S.R.L.
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Senseonics, A.
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Novo Nordisk A/S
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. GlySens Incorporated
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Johnson And Johnson
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. DexCom, Inc.
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Medtronic Plc
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. F. Hoffman-La Roche Ltd
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Abbott Laboratories
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. B. Braun SE
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL GLUCOSE MONITORING DEVICES MARKET, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 2. GLUCOSE MONITORING DEVICES MARKET FOR BLOOD GLUCOSE METERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. GLUCOSE MONITORING DEVICES MARKET FOR CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. GLUCOSE MONITORING DEVICES MARKET FOR FLASH GLUCOSE MONITORING SYSTEMS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. GLUCOSE MONITORING DEVICES MARKET FOR SMARTPHONE APPS AND WEARABLES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 6. GLOBAL GLUCOSE MONITORING DEVICES MARKET, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 7. GLUCOSE MONITORING DEVICES MARKET FOR TYPE 1 DIABETES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. GLUCOSE MONITORING DEVICES MARKET FOR TYPE 2 DIABETES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. GLOBAL GLUCOSE MONITORING DEVICES MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 10. GLUCOSE MONITORING DEVICES MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 11. GLUCOSE MONITORING DEVICES MARKET FOR HOME CARE SETTINGS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. GLUCOSE MONITORING DEVICES MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. GLUCOSE MONITORING DEVICES MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. NORTH AMERICA GLUCOSE MONITORING DEVICES, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 15. NORTH AMERICA GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 16. NORTH AMERICA GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 17. NORTH AMERICA GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 18. U.S. GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 19. U.S. GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 20. U.S. GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 21. CANADA GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 22. CANADA GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 23. CANADA GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 24. MEXICO GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 25. MEXICO GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 26. MEXICO GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 27. EUROPE GLUCOSE MONITORING DEVICES, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 28. EUROPE GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 29. EUROPE GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 30. EUROPE GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 31. FRANCE GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 32. FRANCE GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 33. FRANCE GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 34. GERMANY GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 35. GERMANY GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 36. GERMANY GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 37. ITALY GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 38. ITALY GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 39. ITALY GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 40. SPAIN GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 41. SPAIN GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 42. SPAIN GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 43. UK GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 44. UK GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 45. UK GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 46. REST OF EUROPE GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 47. REST OF EUROPE GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 48. REST OF EUROPE GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 49. ASIA-PACIFIC GLUCOSE MONITORING DEVICES, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 50. ASIA-PACIFIC GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 51. ASIA-PACIFIC GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 52. ASIA-PACIFIC GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 53. CHINA GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 54. CHINA GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 55. CHINA GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 56. JAPAN GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 57. JAPAN GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 58. JAPAN GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 59. INDIA GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 60. INDIA GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 61. INDIA GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 62. SOUTH KOREA GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 63. SOUTH KOREA GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 64. SOUTH KOREA GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 65. AUSTRALIA GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 66. AUSTRALIA GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 67. AUSTRALIA GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 68. REST OF ASIA-PACIFIC GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 69. REST OF ASIA-PACIFIC GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 70. REST OF ASIA-PACIFIC GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 71. LAMEA GLUCOSE MONITORING DEVICES, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 72. LAMEA GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 73. LAMEA GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 74. LAMEA GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 75. BRAZIL GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 76. BRAZIL GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 77. BRAZIL GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 78. SOUTH AFRICA GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 79. SOUTH AFRICA GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 80. SOUTH AFRICA GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 81. SAUDI ARABIA GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 82. SAUDI ARABIA GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 83. SAUDI ARABIA GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 84. REST OF LAMEA GLUCOSE MONITORING DEVICES, BY DEVICE, 2024 - 2033 ($BILLION)
TABLE 85. REST OF LAMEA GLUCOSE MONITORING DEVICES, BY PATIENT TYPE, 2024 - 2033 ($BILLION)
TABLE 86. REST OF LAMEA GLUCOSE MONITORING DEVICES, BY END USER, 2024 - 2033 ($BILLION)
TABLE 87. MENARINI DIAGNOSTICS S.R.L.: KEY EXECUTIVES
TABLE 88. MENARINI DIAGNOSTICS S.R.L.: COMPANY SNAPSHOT
TABLE 89. MENARINI DIAGNOSTICS S.R.L.: OPERATING SEGMENTS
TABLE 90. MENARINI DIAGNOSTICS S.R.L.: PRODUCT PORTFOLIO
TABLE 91. MENARINI DIAGNOSTICS S.R.L.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 92. SENSEONICS, A.: KEY EXECUTIVES
TABLE 93. SENSEONICS, A.: COMPANY SNAPSHOT
TABLE 94. SENSEONICS, A.: OPERATING SEGMENTS
TABLE 95. SENSEONICS, A.: PRODUCT PORTFOLIO
TABLE 96. SENSEONICS, A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97. NOVO NORDISK A/S: KEY EXECUTIVES
TABLE 98. NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 99. NOVO NORDISK A/S: OPERATING SEGMENTS
TABLE 100. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 101. NOVO NORDISK A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102. GLYSENS INCORPORATED: KEY EXECUTIVES
TABLE 103. GLYSENS INCORPORATED: COMPANY SNAPSHOT
TABLE 104. GLYSENS INCORPORATED: OPERATING SEGMENTS
TABLE 105. GLYSENS INCORPORATED: PRODUCT PORTFOLIO
TABLE 106. GLYSENS INCORPORATED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107. JOHNSON AND JOHNSON: KEY EXECUTIVES
TABLE 108. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 109. JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 110. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 111. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112. DEXCOM, INC.: KEY EXECUTIVES
TABLE 113. DEXCOM, INC.: COMPANY SNAPSHOT
TABLE 114. DEXCOM, INC.: OPERATING SEGMENTS
TABLE 115. DEXCOM, INC.: PRODUCT PORTFOLIO
TABLE 116. DEXCOM, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 117. MEDTRONIC PLC: KEY EXECUTIVES
TABLE 118. MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 119. MEDTRONIC PLC: OPERATING SEGMENTS
TABLE 120. MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 121. MEDTRONIC PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 122. F. HOFFMAN-LA ROCHE LTD: KEY EXECUTIVES
TABLE 123. F. HOFFMAN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 124. F. HOFFMAN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 125. F. HOFFMAN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 126. F. HOFFMAN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 127. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 128. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 129. ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 130. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 131. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 132. B. BRAUN SE: KEY EXECUTIVES
TABLE 133. B. BRAUN SE: COMPANY SNAPSHOT
TABLE 134. B. BRAUN SE: OPERATING SEGMENTS
TABLE 135. B. BRAUN SE: PRODUCT PORTFOLIO
TABLE 136. B. BRAUN SE: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL GLUCOSE MONITORING DEVICES MARKET SEGMENTATION
FIGURE 2. GLOBAL GLUCOSE MONITORING DEVICES MARKET
FIGURE 3. SEGMENTATION GLUCOSE MONITORING DEVICES MARKET
FIGURE 4. TOP INVESTMENT POCKET IN GLUCOSE MONITORING DEVICES MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALGLUCOSE MONITORING DEVICES MARKET
FIGURE 11. GLOBAL GLUCOSE MONITORING DEVICES MARKET SEGMENTATION, BY DEVICE
FIGURE 12. GLUCOSE MONITORING DEVICES MARKET FOR BLOOD GLUCOSE METERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. GLUCOSE MONITORING DEVICES MARKET FOR CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. GLUCOSE MONITORING DEVICES MARKET FOR FLASH GLUCOSE MONITORING SYSTEMS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. GLUCOSE MONITORING DEVICES MARKET FOR SMARTPHONE APPS AND WEARABLES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. GLOBAL GLUCOSE MONITORING DEVICES MARKET SEGMENTATION, BY PATIENT TYPE
FIGURE 17. GLUCOSE MONITORING DEVICES MARKET FOR TYPE 1 DIABETES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 18. GLUCOSE MONITORING DEVICES MARKET FOR TYPE 2 DIABETES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. GLOBAL GLUCOSE MONITORING DEVICES MARKET SEGMENTATION, BY END USER
FIGURE 20. GLUCOSE MONITORING DEVICES MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. GLUCOSE MONITORING DEVICES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. GLUCOSE MONITORING DEVICES MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 23. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 24. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 25. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 26. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 27. COMPETITIVE DASHBOARD
FIGURE 28. COMPETITIVE HEATMAP: GLUCOSE MONITORING DEVICES MARKET
FIGURE 29. TOP PLAYER POSITIONING, 2023
FIGURE 30. MENARINI DIAGNOSTICS S.R.L.: NET SALES, 2021-2023 ($BILLION)
FIGURE 31. MENARINI DIAGNOSTICS S.R.L.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 32. MENARINI DIAGNOSTICS S.R.L.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 33. SENSEONICS, A.: NET SALES, 2021-2023 ($BILLION)
FIGURE 34. SENSEONICS, A.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 35. SENSEONICS, A.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 36. NOVO NORDISK A/S: NET SALES, 2021-2023 ($BILLION)
FIGURE 37. NOVO NORDISK A/S: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. NOVO NORDISK A/S: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. GLYSENS INCORPORATED: NET SALES, 2021-2023 ($BILLION)
FIGURE 40. GLYSENS INCORPORATED: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. GLYSENS INCORPORATED: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. JOHNSON AND JOHNSON: NET SALES, 2021-2023 ($BILLION)
FIGURE 43. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. DEXCOM, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 46. DEXCOM, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. DEXCOM, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. MEDTRONIC PLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 49. MEDTRONIC PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. MEDTRONIC PLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. F. HOFFMAN-LA ROCHE LTD: NET SALES, 2021-2023 ($BILLION)
FIGURE 52. F. HOFFMAN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. F. HOFFMAN-LA ROCHE LTD: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 54. ABBOTT LABORATORIES: NET SALES, 2021-2023 ($BILLION)
FIGURE 55. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 56. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 57. B. BRAUN SE: NET SALES, 2021-2023 ($BILLION)
FIGURE 58. B. BRAUN SE: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 59. B. BRAUN SE: REVENUE SHARE, BY REGION, 2023 (%)

Companies Mentioned

  • Menarini Diagnostics S.R.L.
  • Senseonics, A.
  • Novo Nordisk A/S
  • GlySens Incorporated
  • Johnson & Johnson
  • DexCom, Inc.
  • Medtronic plc
  • F. Hoffman-La Roche Ltd
  • Abbott laboratories
  • B. Braun SE

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information